机器学习预测重度硬皮病干细胞移植应答
SCOT试验比较了造血干细胞移植(HSCT)与环磷酰胺(CYC)治疗重度系统性硬化症(SSc)的疗效。本研究对63例SCOT参与者基线与随访外周血细胞基因表达分析,发现纤维增殖亚型患者接受HSCT较CYC的无事件生存(EFS)显著改善(p=0.0091),而正常样亚型(p=0.77)和炎症亚型(p=0.1)两臂EFS无显著差异。提示基于内在亚型分层可识别从HSCT显著获益的SSc患者。
要点
- 纤维增殖亚型SSc患者接受HSCT较CYC的EFS显著改善(p=0.0091)。
- 正常样亚型(p=0.77)和炎症亚型(p=0.1)两治疗臂EFS无显著差异。
- HSCT臂较CYC臂在各时间点有更多差异表达基因,免疫应答通路显著改变。
核心结论
- 纤维增殖亚型患者从HSCT较CYC获得最显著的长期获益,内在亚型分层可用于识别从HSCT显著获益的SSc患者。
研究设计与样本
- 基于SCOT临床试验,分析63例参与者基线与随访时间点的外周血细胞基因表达数据,按基线内在基因表达亚型分层评估无事件生存(EFS)并分析差异表达基因(DEGs)。
主要发现
- 纤维增殖亚型中HSCT较CYC的EFS显著改善(p=0.0091)。
- 正常样亚型(p=0.77)和炎症亚型(p=0.1)中CYC与HSCT两臂EFS无显著差异。
- 各时间点HSCT臂较CYC臂观察到更多DEGs,HSCT臂免疫应答通路呈显著改变。
关键数值与推荐
- 纤维增殖亚型HSCT vs CYC的EFS比较p=0.0091。
- 正常样亚型HSCT vs CYC的EFS比较p=0.77。
- 炎症亚型HSCT vs CYC的EFS比较p=0.1。
临床怎么用
- 对重度SSc患者可考虑基于外周血基因表达内在亚型分层,纤维增殖亚型者HSCT较CYC可能获得更显著的长期无事件生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated clinical benefit of haematopoietic stem cell transplant (HSCT) compared with cyclophosphamide (CYC). We mapped PBC (peripheral blood cell) samples from the SCOT clinical trial to scleroderma intrinsic subsets and tested the hypothesis that they predict long-term response to HSCT. METHODS: We analysed gene expression from PBCs of SCOT participants to identify differential treatment response. PBC gene expression data were generated from 63 SCOT participants at baseline and follow-up timepoints. Participants who completed treatment protocol were stratified by intrinsic gene expression subsets at baseline, evaluated for event-free survival (EFS) and analysed for differentially expressed genes (DEGs). RESULTS: Participants from the fibroproliferative subset on HSCT experienced significant improvement in EFS compared with fibroproliferative participants on CYC (p=0.0091). In contrast, EFS did not significantly differ between CYC and HSCT arms for the participants from the normal-like subset (p=0.77) or the inflammatory subset (p=0.1). At each timepoint, we observed considerably more DEGs in HSCT arm compared with CYC arm with HSCT arm showing significant changes in immune response pathways. CONCLUSIONS: Participants from the fibroproliferative subset showed the most significant long-term benefit from HSCT compared with CYC. This study suggests that intrinsic subset stratification of patients may be used to identify patients with SSc who receive significant benefit from HSCT.
引用
- Franks JM, Martyanov V, Wang Y, et al. Machine learning predicts stem cell transplant response in severe scleroderma. Ann Rheum Dis. 2020. PMID: 32933919. doi:10.1136/annrheumdis-2020-217033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。